Radiologically Isolated Syndrome Clinical Trials

A listing of Radiologically Isolated Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 124 clinical trials
Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis

The hypothesis of the study is that according to modern data, the pathogenesis of multiple sclerosis is inextricably linked to the patient's microbiota. Therefore, transplantation of a normal fecal microbiota (FMT) can improve the outcome of autologous hematopoietic stem cell transplantation (autoHSCT) by increasing the disease-free period and disease progression …

rituximab
cyclophosphamide
disease or disorder
  • 0 views
  • 04 Oct, 2022
  • 1 location
Application of ihMT MRI in Multiple Sclerosis (ihMTMS)

The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer …

MRI
demyelination
disease or disorder
brain mri
relapsing multiple sclerosis
  • 4 views
  • 04 Oct, 2022
  • 1 location
MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis (SEP-MRI)

Multiple sclerosis (MS) is the first non-traumatic cause of disability in young people, responsible for physical but also cognitive deficits. MS is an inflammatory demyelinating and degenerative disease of the central nervous system. Recently, MRI technics have demonstrated their sensibility to the different processes involved in MS. Particularly, MRI has …

MRI
demyelination
disease or disorder
nervous
cognitive deficits
  • 14 views
  • 04 Oct, 2022
  • 1 location
Profile of Adherence to Therapy and Interventions to Promote Adherence in MS

Adherence is an active process wherein the patient acts in collaboration with the medical and paramedical staff in order to improve his/her health. Adherence to medication comprises of implementation and persistence and it is estimated to be around 50% in various chronic illnesses, including Multiple Sclerosis (MS). MS patients who …

chronic disease
disease or disorder
nervous
  • 7 views
  • 04 Oct, 2022
  • 1 location
The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study

Background Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways. Sometimes they light up from the outer edge and fill inward. This is called ring enhancement. Researchers think this type of lesion may not …

MRI
myelopathies
prednisone
brain mri
methylprednisolone
  • 26 views
  • 13 Oct, 2022
  • 1 location
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Background In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might …

rituximab
disease or disorder
fingolimod
copaxone
alemtuzumab
  • 34 views
  • 25 Oct, 2022
  • 1 location
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive orally administered ozanimod HCl 1 mg. The primary efficacy endpoint is …

relapsing multiple sclerosis
  • 279 views
  • 28 Oct, 2022
  • 59 locations
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis (NEXT-MS)

Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab infusions. Natalizumab trough concentrations after a 4-weekly interval are high in the large majority of patients which implies a relative overdose in most patients. …

progressive multifocal leukoencephalopathy
relapsing multiple sclerosis
natalizumab
disease or disorder
  • 7 views
  • 24 Feb, 2022
  • 17 locations
Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

The aim of this project is to assess properly the clinical efficacy of TolDec therapy by imaging, clinical and surrogate end-points related with the activity of the disease.

  • 0 views
  • 19 Feb, 2021
  • 5 locations
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

This is a phase IIa study with GA Depot in subjects with Primary Progressive MS. GA Depot will be administered intramuscularly (IM), once every four weeks for 148 weeks. The purpose of this study is to assess the safety and efficacy of GA Depot to slow the accumulation of disability …

disease or disorder
glatiramer acetate
  • 26 views
  • 22 Aug, 2021
  • 16 locations